Tyrosine kinase LYN is an oncotarget in human cervical cancer: A quantitative proteomic based study.
Cervical cancer is one of the most common malignant tumor in women. The mechanisms of cervical cancer are intricate and have not been fully understood. Therefore, we employed iTRAQ to obtain novel proteins profile which participates in the tumor oncogenesis of cervical cancer. 3300 proteins were identified aberrantly expressed in cervical cancer, and western bolt was performed to validate the results of iTRAQ. Then, we selected LYN for further study. Immunohistochemistry identified that LYN expression was significantly increased in cervical cancer tissues than that in cancer adjacent normal cervical tissues and normal cervical tissues. The increased LYN expression was significantly correlated with cancer differentiation and FIGO stage. Silencing LYN inhibited cell proliferation, migration and invasion, conversely, overexpression LYN promoted cell proliferation, migration and invasion. In terms of mechanism, LYN could also promote cervical cancer cells metastasis through activating IL-6/STAT3 pathway. In vivo study, overexpression LYN promoted tumor growth, meanwhile knockdown LYN inhibited tumor growth. These results indicate that LYN tyrosine kinase is an oncogenic gene and can serve as a novel target for cervical cancer research and therapy.
Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, PR China.
Shuaibin
S
Liu
Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, PR China.
Xiaoming
X
Hao
Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, PR China.
Xiaolan
X
Ouyang
Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, PR China.
Xiaojing
X
Dong
Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, PR China.
Yixuan
Y
Yang
Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, PR China.
Tinghe
T
Yu
Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, PR China.
Jianguo
J
Hu
Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, PR China.
Lina
L
Hu
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D045744:Cell Line, Tumor; D002465:Cell Movement; D049109:Cell Proliferation; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism; D058990:Molecular Targeted Therapy; D009367:Neoplasm Staging; D015513:Oncogene Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D011485:Protein Binding; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D020543:Proteome; D040901:Proteomics / Q000379:methods; D050796:STAT3 Transcription Factor / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D002583:Uterine Cervical Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D019061:src-Family Kinases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*
D000970:Antineoplastic Agents; D015850:Interleukin-6; D015513:Oncogene Proteins; D047428:Protein Kinase Inhibitors; D020543:Proteome; D050796:STAT3 Transcription Factor; C060902:lyn protein-tyrosine kinase; D019061:src-Family Kinases
IL-6; LYN; STAT3; cervical cancer; iTRAQ
Semin Immunol. 2014 Feb;26(1):38-47
24602448
Mol Cell Proteomics. 2007 Dec;6(12):2072-87
17855441
Oncogenesis. 2014 Aug 18;3:e115
25133482
Br J Pharmacol. 2014 Dec;171(24):5507-23
24665826
Br J Cancer. 2010 Sep 7;103(6):899-909
20717116
PLoS One. 2013 Aug 01;8(8):e70353
23936413
PLoS One. 2014 Jul 16;9(7):e102610
25029526
Nat Rev Cancer. 2009 Nov;9(11):798-809
19851315
Br J Cancer. 2012 Aug 21;107(5):856-63
22814579
Methods. 2001 Dec;25(4):402-8
11846609
J Immunol. 1999 Oct 15;163(8):4192-8
10510355
J Proteome Res. 2013 May 3;12(5):2078-89
23510160
J Proteomics. 2014 Jun 25;106:99-112
24769235
Lancet. 2014 Feb 8;383(9916):524-32
24192252
Nat Rev Clin Oncol. 2009 Oct;6(10):587-95
19787002
J Infect. 2013 Mar;66(3):207-17
23103285
Eur J Cancer. 2013 Dec;49(18):3889-99
23953057
Blood. 2008 Apr 1;111(7):3821-9
18235045
PLoS One. 2015 Oct 13;10(10):e0140492
26460485
J Proteome Res. 2007 Feb;6(2):821-7
17269738
Semin Immunol. 2014 Feb;26(1):54-74
24552665
Oncogene. 2004 Oct 18;23(48):7906-9
15489908
Mol Cell Proteomics. 2004 Dec;3(12):1154-69
15385600
Mol Cancer. 2012 Jun 26;11:43
22731636
Anal Bioanal Chem. 2012 Sep;404(4):1011-27
22451173
Cancer Lett. 2009 Aug 28;281(2):151-61
19307055